Small fiber neuropathy in Fabry disease (Q38002142)

26 August 2017

Small fiber neuropathy in Fabry disease (English)

1 reference

26 August 2017

1 reference

Marieke Biegstraaten

1

1 reference

26 August 2017

Carla E M Hollak

2

1 reference

26 August 2017

Mayienne Bakkers

3

1 reference

26 August 2017

Catharina G Faber

4

1 reference

26 August 2017

Johannes M F G Aerts

5

1 reference

26 August 2017

Ivo N van Schaik

6

1 reference

26 August 2017

24 March 2012

1 reference

Molecular Genetics and Metabolism

26 August 2017

1 reference

26 August 2017

106

1 reference

26 August 2017

2

1 reference

26 August 2017

135-141

1 reference

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Myelinated nerve endings in human skin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Enzyme replacement therapy and intraepidermal innervation density in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

The relation between small nerve fibre function, age, disease severity and pain in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Neuropathic symptoms and findings in women with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Small fiber dysfunction predominates in Fabry neuropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Physiological characterization of neuropathy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Detection of a characteristic painful neuropathy in Fabry disease: a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Neurology of Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Pathological study of the sural nerve in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Quantitative analysis of epidermal innervation in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

EFNS guidelines on neuropathic pain assessment: revised 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Fabry disease: impaired autonomic function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Peripheral hemodynamics in patients with Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Small-fibre neuropathy in female Fabry patients: reduced allodynia and skin blood flow after topical capsaicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Cardiac manifestations of Anderson-Fabry disease in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Enhanced endothelium-dependent vasodilation in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Autonomic neuropathy, I. Clinical features, investigation, pathophysiology, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Hereditary sensory neuropathy with neurotrophic keratitis. Description of an autosomal recessive disorder with a selective reduction of small myelinated nerve fibres and a discussion of the classification of the hereditary sensory neuropathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

Hereditary sensory neuropathy type I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.03.010

10.1016/J.YMGME.2012.03.010

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference